CCO Treatment Updates
Hepatitis C Advanced Practice Curriculum 2009
Interactive Virtual Presentations
2009 HCV Advanced Practice Curriculum: The Importance of Patient Quality of Life
|
Program Director: Gary L. Davis, MD
|
|
Vinod Rustgi, MD, discusses how hepatitis C infection impacts quality of life and how quality of life can impact the outcome of hepatitis C therapy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the variety of factors which may impact a patient’s quality of life
- Explain how hepatitis C and its treatment affect quality of life
- Recall how quality of life can impact a patient’s adherence to hepatitis C therapy
- Summarize the effects of attaining SVR on quality of life
|
Slideset: The Importance of Patient Quality of Life
 |
|
In this downloadable slideset, Vinod Rustgi, MD, discusses how hepatitis C infection impacts quality of life and how quality of life can impact the outcome of hepatitis C therapy.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.14 MB
| Date posted: 4/7/2009
|
2009 HCV Advanced Practice Curriculum: Current Management of HCV Treatment-Experienced Patients
|
Program Director: Gary L. Davis, MD
- Maria H. Sjogren, MD, MPH, FACP
|
|
|
Maria H. Sjogren, MD, MPH, FACP, discusses current management options for HCV-infected, treatment-experienced patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall the rationale behind retreating standard interferon and peginterferon nonresponders
- Discuss the various management options for retreating standard interferon and peginterferon nonresponders
- Explain the differences in relapse rates between relapsers and nonresponders to peginterferon
- Recount the effect of baseline fibrosis on response to retreatment
|
Slideset: Current Management of HCV Treatment-Experienced Patients
 |
|
In this downloadable slideset, Maria H. Sjogren, MD, discusses the rationale for retreating HCV nonresponders and explores treatment options for this subset of patients.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.50 MB
| Date posted: 5/15/2009
|
2009 HCV Advanced Practice Curriculum: Fibrosis and Disease Progression in HCV
|
Program Director: Gary L. Davis, MD
|
|
Raymond T. Chung, MD, reviews complications of advanced liver disease, how to assess the severity of liver disease, and how treatment may address these complications.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall the current and projected burden of hepatitis C–related complications in the United States
- Discuss methods to assess the severity of liver disease
- Recount factors that contribute to the progression of advanced liver disease
- Explain how hepatitis C treatment impacts the natural history of the disease
|
Slideset: Fibrosis and Disease Progression in HCV
 |
|
In this downloadable slideset, Raymond T. Chung, MD, reviews the complications associated with advanced liver disease, how to assess the severity of liver disease, and how treatment may affect outcomes.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.12 MB
| Date posted: 6/12/2009
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|